1. Pink Sheet

Departing Words: Merck’s Ken Frazier Cautions Against Profit Maximization

 
• By Sarah Karlin-Smith

Pharma CEOs must balance optimizing access and profitability, former Merck CEO and soon-to-be ex executive chairman of the company said. Frazier says health care industry must come to table and admit the “system ain’t working,” talks about the need to protect democracy, in a sweeping interview at the STAT Summit.

Kenneth Frazier, Chairman of the Board and CEO of US pharmaceutical company Merck looks on during an event with the French-American Foundation in Paris on July 11, 2018. (Photo by ERIC PIERMONT / AFP) GettyImages-996036844
• Source: Eric Piermont/AFP via Getty Images

Drug industry CEOs must operate differently than the leaders of other businesses due to the role of medicines and ethics around medicine, said Merck & Co., Inc.’s outgoing executive chairman and former CEO Ken Frazier in a 16 November interview just two weeks ahead of his retirement from the pharmaceutical company.

“My personal view is that pharma CEOs can’t simply take the attitude that they are going to maximize financial outcomes,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Agency Leadership

More from Pink Sheet

CAR-T Therapy Trials Involving Chinese Labs Will Face Heightened US FDA Scrutiny

 
• By Michael McCaughan

The FDA wants to ensure participants in clinical trials involving genetic engineering done in China understand what the agency sees as privacy and security risks. The agency also wants cell therapy processing done outside of “hostile” countries.

New CDER Deputy Director Michael Davis Brings Psychedelic Drug Development Experience

 
• By Sue Sutter

Davis, a former FDA team leader in the Division of Psychiatry Products, rejoins the agency from the Usona Institute, which develops psychedelics. His background aligns with Commissioner Martin Makary’s goal of seeing new treatments approved for post-traumatic stress disorder.

EU Sees Unified Pathway For Drug/IVD Studies As Key To Future Research Investment

 
• By Vibha Sharma

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.